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Summary
This paper presents a modern in silico approach useful in the evaluation of proteins as
a source of ACE inhibitors. All protein sequences analyzed were derived from the BIOPEP
database. To determine the protein value, the following criteria of evaluation were applied:
the profile of potential biological (ACE inhibitory) activity of a protein, the frequency of
the occurrence of fragments with ACE inhibitory activity (A) and the potential biological
activity of a protein (B). The results, based on a statistical analysis, indicate that milk pro-
teins can be a better source of ACE inhibitors than wheat gliadins. Moreover, all analyzed
gliadins possessed more potent ACE inhibitors than chicken meat proteins. No significant
differences were observed when comparing A values between soy globulins and b-lacto-
globulins. Although criteria such as the profile of potential biological activity of protein, as
well as parameters A and B, can be suitable tools in protein evaluation, the proteolytic di-
gestion of protein needs to be considered. Moreover, computerised methods of classifying
proteins according to different algorithms are often subjective due to discretion in interpre-
tation of the results.
Key words: proteins, ACE inhibitors, BIOPEP database, in silico methods, biological activity,
functional food
Introduction
There are many lifestyle diseases which cause public
health problems worldwide (1). These diseases include
cardiovascular problems (e.g. atherosclerosis, stroke or
myocardial infarction) (2) as well as their major predis-
posing factors such as hypertension and diabetes (3).
Overconsumption of cheap, energy-dense food and de-
creased physical activity have contributed to the growth
of obesity in both Western and developing countries. Data
from 2007 show that around 1.1 billion adults worldwide
are overweight and 312 million of them are obese (3).
Apart from recommending a healthy lifestyle to pre-
vent the diseases of civilization, many innovative nutri-
tional strategies to reduce the main risk factors have
been elaborated and their effects have been scientifically
demonstrated (4). These strategies include dietary chan-
ges or the consumption of specifically targeted functio-
nal foods and supplements. For example, some food
products and beverages have the appearance of 'normal
food' but contain some specific components that can re-
duce blood pressure and cholesterol level (4). Food-de-
rived bioactive peptides represent a source of health-en-
hancing components (5). Such peptides contribute to the
physiological and sensory properties of protein-rich food.
The health benefits of protein-derived peptides have
been the subject of increasing commercial interest in
health-promoting markets based on the novel concept of
'personalized nutrition' (5). Improvement of the biologi-
cal functions of peptides may lead to providing new
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therapeutic applications for the prevention or treatment
of chronic diseases (6).
Food products, especially dairy ones, are rich in ACE
inhibitory (i.e. reducing blood pressure), antimicrobial,
immunomodulating and many other biologically-active
peptides (5). Bioactive peptides have also been found in
meat, fish, seafood and eggs (7). Depending on the ini-
tial protein source, the enzyme applied and process con-
ditions, the peptide biological activities can differ. For
example, peptides released from soy protein showed anti-
carcinogenic, antioxidant and hypotensive activity (6).
Modern in silico techniques have become common
in the area of food science. Techniques such as QSAR
(quantitative structure-activity relationship) involving PCS
(principal component similarity), HSA (homology simi-
larity analysis) or RCO (random centroid optimization)
have been applied successfully in designing peptides
derived from food proteins (8). For example, homology
similarity analysis (HSA) developed by Nakai et al. (9)
facilitated the elucidation of the structure-function rela-
tionships of lactoferricin derivatives. The RCO proce-
dure was applied for the modification of a single site of
sixteen amino acids at the site of Bacillus stearothermo-
philus neutral protease to improve its thermostability
(10). A number of peptides have been discovered, usu-
ally in vitro, based on their biological activities or in
silico, based on their sequence similarities. Searching da-
tabases such as Swiss-Prot and Trembl and using BLAST
alignment tools and other in silico methods, all currently
known bioactive peptides and their precursor proteins
can be extracted and provide information about the
function and similarities between sequence motifs (11–13).
Another bioactive peptide database, BIOPEP, provides
data on over 2000 peptides with various activities (14).
BIOPEP can be a useful tool in the area of prediction of
the possibilities to release biologically active peptides
(15) as well as the classification of proteins based on
specially designed criteria (16).
According to Minkiewicz et al. (17) there is still a
need to study and develop new technologies, both ex-
perimental and computational, which retain or even en-
hance the activity of bioactive peptides in food systems.
Thus, in this study a method is proposed involving in
silico techniques to compare plant and animal proteins
as a source of ACE inhibitors which should be a suitable
tool in the potential evaluation of protein sequences. Due
to the fact that bioactive peptides are a well-known group
occurring in their precursor sequences, it was assumed
that peptides with the above-mentioned activity should
appear in the great majority of proteins to be compared.
This is consistent with previous studies which indicated
that motifs with ACE inhibitory activity usually domi-
nated in the analyzed protein sequences (18).
Materials and Methods
Protein sequences were extracted from the BIOPEP
database available on the Internet at http://www.uwm.edu.pl/
biochemia (14,16). The sequences analyzed in this study
can be found in the BIOPEP database with the following
ID numbers: 1076, 1077, 1078, 1079, 1081, 1082, 1083,
1085, 1086, 1087, 1088, 1089, 1090, 1091, 1092, 1093, 1094,
1095, 1097, 1098, 1099, 1100, 1101, 1102, 1103, 1104, 1105,
1106, 1107, 1108, 1109, 1111, 1112, 1113, 1114, 1115, 1116,
1117, 1120, 1121, 1122, 1126, 1128, 1130, 1133, 1134, 1140,
1141, 1142, 1143, 1144, 1148, 1149, 1150, 1152, 1153, 1154,
1155, 1161, 1162, 1163, 1164, 1167, 1168, 1169, 1170, 1171,
1172, 1173, 1174, 1175, 1176, 1177, 1178, 1179, 1180, 1181,
1182, 1183, 1184, 1186, 1193, 1196, 1197, 1198, 1199, 1200,
1273, 1317, 1318, 1319, 1320, 1365, 1550 and 1564.
The sequences of peptides with ACE inhibitory ac-
tivity which are available in BIOPEP were derived from
the literature resources. According to the references,
these peptides are mainly described as ACE (angioten-
sin I-converting enzyme, EC 3.4.15.1) inhibitors. This
means they inhibit the hydrolysis of angiotensin I to an-
giotensin II, which is known as one of the most impor-
tant vasoconstrictors. Some of the ACE inhibitors showed
an antihypertensive effect in vivo in spontaneously hy-
pertensive rats (19).
BIOPEP is systematically and continuously updated
with the 'new' sequences of peptides with different ac-
tivities. It practically means that any single insertion of
the 'new' peptide to the database or its deletion from it
affects the values of discriminants A and B.
To compare the protein sequences, the following cri-
teria were applied: (i) the profile of potential biological
(ACE inhibitory) activity of a protein which is defined
as the type and the location of ACE inhibitory fragment
in a protein sequence; (ii) the occurrence frequency of
the fragments with an ACE inhibitory activity in poly-
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where ai is the number of repetitions of the i-th bioactive
fragment in protein sequence, EC50i is the concentration
of the i-th bioactive peptide corresponding to half of its
maximal activity (mM), k is the number of different frag-
ments with ACE inhibitory activity, and N is the num-
ber of amino acid residues (16).
The above-mentioned discriminants of protein value
were computed automatically by BIOPEP after the selec-
tion of the protein sequence to analyze (see a toolbar
called 'Analysis' available in protein and bioactive pep-
tide databases).
Due to the fact that BIOPEP is a universal database
containing peptides with over forty types of activities,
the EC50 (if available), which characterizes the given ac-
tivity of the peptide, is taken into consideration to calcu-
late B. According to the references concerning the ACE
inhibitors, the measure of their activity is IC50, defined
as the sample concentration required to inhibit 50 % of
the ACE activity (20). The ACE activity can be quanti-
fied colorimetrically, fluorometrically, radiochemically
and chromatographically (21). The popular assays to de-
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termine the ACE activity involve hippuryl-histidyl-leu-
cine (HHL) (22) and/or furanacryloyl-L-phenylalanylgly-
cylglycine (FAPGG) (21) as substrates. According to the
HHL assay, the above-mentioned substrate is cleaved by
angiotensin-converting enzyme (ACE) to release hippu-
ric acid, which can be quantified spectrophotometrically
at 228 nm. Thus, ACE inhibitory peptides will inhibit
the formation of hippuric acid and it will affect the ab-
sorbance value (the lower the value, the more potent the
peptide) (22). In the second assay, FAPGG is hydrolyzed
to furanacryloyl-L-phenylalanine (FAP) and glycylgly-
cine (GG), and the absorption spectrum is between 328
and 352 nm (21).
To conclude, if the BIOPEP user decides to calculate
the potential ACE inhibitory activity for the given pro-
tein (B), the value of IC50 will be the component of the
equation defined as parameter B.
A t-test was performed to find statistically signifi-
cant differences between groups of proteins – precursors
of ACE inhibitors. This test was performed using Sta-
tistica v. 8 software.
Results and Discussion
The profiles of the potential ACE inhibitory activity
of the analyzed proteins revealed the presence of ACE
inhibitors. The number of fragments with this activity
that appeared in the protein sequences varied depend-
ing on the length of the protein chain (the longer the
chain, the higher the probability to find more fragments
in it) (23). As an example of such a profile, the ACE in-
hibitory characteristics of chicken connectin (Gallus gallus)
are presented in Fig. 1. Fragments which are ACE inhib-
itors are underlined. The entire sequence of this protein
consists of 1021 amino acid residues and includes 162
fragments with the above-mentioned activity. They are
mostly di- and tripeptides. It should be noted that some
of the biopeptides are part of the longer sequence, e.g.
the chain position 519–527 (YKDGKKLKE) includes the
following ACE inhibitory dipeptides: YK, DG, GK, KL
and KE. This is important in terms of easier absorption
of short peptides to blood in comparison with free ami-
no acids (23).
The shortest protein analyzed was a fragment of mo-
nellin B (BIOPEP ID-1169), which consists of fifty amino
acid residues. Twenty-one ACE inhibitory peptides (two
tripeptides and nineteen dipeptides) were found in this
protein fragment.
Milk is known as a complex of various nutrients
and bioactive components (24). By submitting milk to an
analysis of potential ACE inhibitory activity profiles for
all analyzed sequences, it was confirmed that milk pro-
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Fig. 1. An example of the profile of potential ACE inhibitory activity performed for the chicken (Gallus gallus) connectin 1 (BIOPEP
ID-1118)
teins contained the largest number of ACE inhibitors re-
garding the length of the protein chain (16). Figs. 2 and
3 show the newly BIOPEP-generated profiles of the ACE
inhibitors in the a-lactalbumins derived from different
sources and different variants of bovine b-casein, respec-
tively.
Generally, in the case of a-lactalbumins, from seven
out of eight species analyzed, the number of potential
ACE inhibitors was comparable (from 38 to 45). The bo-
vine precursor of lactalbumin (ID-1115) possessed the
largest number of potential ACE inhibitors (45). The
smallest number (31) of peptides lowering blood pres-
sure was found in guinea pig (Cavia porcellus). Peptides
consisting of two amino acid residues dominated in
these proteins, but also the presence of longer fragments
such as LAHKAL, WLAHK and VGINYWLAHK was
observed.
Fig. 3 shows the profiles of ACE inhibitors in ge-
netic variants of bovine b-casein (Bos taurus). The entire
sequence of casein consists of 209 amino acid residues.
All genetic variations are highlighted in red. The change
of serine for arginine at position 122 of the casein chain
in genetic variant B contributed to the increase of the
number of potential ACE inhibitors. Variant B of casein
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Fig. 2. An example of the profiles of potential ACE inhibitory activity performed for the a-lactalbumins derived from different sources
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Fig. 3. Examples of the profile of potential ACE inhibitory activity performed for different genetic variants of bovine (Bos taurus) b-caseins
was the best source of ACE inhibitors (121). The small-
est number of peptides was observed in variant F, where
proline was changed for leucine at position 152 of the
protein chain. Proline is the most common C-terminal
residue occurring in ACE inhibitors and, with other cy-
clic or aromatic amino acids, is involved in the activity
of the peptide (19). Apart from short chain fragments,
caseins were in the group of proteins containing the long-
est peptides known as ACE inhibitors, such as e.g.
LPQNIPPLTQTPVVVPPFLQPEVMGVSK, KYPVQPFTE-
SQSLTL, KIHPFAQTQSLVYP and LVYPFPGPIPNSLPQ-
NIPP.
The profiles of the biological activity of the ana-
lyzed proteins showed that some of them had not been
known so far as endogenous ACE inhibitors (e.g. chicken
myosin). This confirms the hypothesis by Karelin et al.
(25) that, regardless of their basic functions, proteins can
be the precursors of peptides with different types of bio-
activity.
According to Dziuba and Iwaniak (14), the profile of
potential biological activity of a protein gives an answer
to the following question: are there any bioactive frag-
ments that may occur in a protein? If the answer is posi-
tive, it suggests that protein may be a precursor of bio-
peptides, but we need to be aware of metabolic processes
in the body. The enzymatic action of specific enzymes
can contribute to the release of peptides with (not neces-
sarily) ACE inhibitory activity. Fukudome et al. (26)
showed that the opioid activity of gluten hydrolysates
varied depending on the applied hydrolytic enzyme.
Adequate proteolysis can facilitate the release of bio-
active peptides and their bioactivity can decrease due to
exceeding a certain level of hydrolysis (15). The effec-
tiveness of peptide action can also be dependent on
their hydrolysis resistance in the digestive tract, as well
as on blood absorption (27). To predict the possibility
and number of released peptides after the action of dif-
ferent proteolytic enzymes, Dziuba and Iwaniak (14) de-
veloped an option called 'The Enzymes' Action', which is
available in the BIOPEP database. There are many bioin-
formatic tools predicting enzymatic hydrolysis of proteins
and they are based on different algorithms. They have
become popular in proteolytic process design (28,29).
Table 1 shows the values of the frequency of the oc-
currence of ACE inhibitors (A) as well as the potential
ACE inhibitory activity of protein fragments (B). The
values of A are given in ascending order. The relatively
highest values of A discriminant were obtained for milk
and meat proteins: bovine b-caseins (Bos taurus) (A in
the range from 0.536 to 0.569), bovine tropoelastin (Bos
taurus) (A=0.885), and chicken (Gallus gallus) and bovine
(Bos taurus) collagens (A=0.751 and 0.874, respectively).
The lowest values of the frequency of occurrence of ACE
inhibitory fragments appeared in plant proteins from
rice and wheat, or animal origin sequences such as lyso-
zymes and short-chained meat proteins (e.g. from chick-
en). The exception was the relatively high value of A
calculated for monellin (blueberry) (A=0.511) and wheat
glutenin (A=0.558). This could be explained by the over-
lapping sequences of peptides (monellin) and the length
of the protein chain (glutenin).
The values of potential biological activity (B), defined
as the sum of the individual ACE inhibitory fragments
within the above-mentioned protein sequences were:
0.0176–0.0194 (b-caseins), 0.0209 (bovine tropoelastin),
0.2340 (chicken collagen) and 0.2720 (bovine collagen).
There is no simple relationship between the fre-
quency of occurrence of bioactive fragments in a given
protein and its potential biological activity. For example,
the frequency of the occurrence of ACE inhibitors in col-
lagens is over threefold higher than in rice prolamins
(Table 1). However, the potential ACE inhibitory activity
of collagens is much higher, compared to rice prolamins.
This results from the fact that fragments showing ACE
inhibitory activity found in rice prolamins are more po-
tent inhibitors of ACE than the corresponding fragments
of collagens.
In conclusion, the higher the value of A, the higher
the probability of enzymatic release of peptides from
their protein precursors. In turn, lower values of B sug-
gest that fragments present in a protein are more potent.
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Table 1. The frequency of the occurrence of ACE inhibitory
fragments (A) and potential ACE inhibitory activity (B) in the
analyzed protein sequences
No. Protein A B/mM–1
1. rice 10KD prolamin [precursor], ID-1168 0.240 0.0015
2. 13 kDa prolamin [precursor], rice,
ID-1550
0.250 0.0170
3. a-lactalbumin, guinea pig, ID-1083 0.252 0.0060
4. rice prolamin [precursor], CLONE
PPROL 17, ID-1153
0.262 0.0148
5. a-lactalbumin, red-necked wallaby,
ID-1081
0.264 0.0083
6. tropomyosin 1 a chain, chicken, ID-1128 0.278 0.0031
7. legumin A [precursor] (b-globulin),
ID-1164
0.286 0.0044
8. a/b-gliadin [precursor] (prolamin)
(class A-I), wheat, ID-1177
0.290 0.0075
9. a/b-gliadin [precursor] (prolamin),
wheat, ID-1365
0.292 0.0065
10. lysozyme [precursor], silk moth, ID-1093 0.292 0.0111
11. purothionin A-I [precursor]
(b-purothionin), wheat, ID-1173
0.294 0.0052
12. lysozyme C, dog, ID-1094 0.294 0.0126
13. lysozyme C, domestic pigeon, ID-1095 0.299 0.0099
14. sorghum kafirin PGK1 [precursor],
ID-1149
0.301 0.0043
15. a/b-gliadin [precursor] (prolamin)
(clone PW8142), wheat, ID-1184
0.304 0.0083
16. g-gliadin, wheat, ID-1318 0.304 0.0064
17. C troponin skeletal muscles, chicken,
ID-1133
0.304 0.0066
18. a/b-gliadin [precursor] (prolamin)
(class A-IV), wheat, ID-1183
0.306 0.0084
19. a/b-gliadin [precursor] (prolamin)
(class A-II), wheat, ID-1178
0.306 0.0049
20. g-gliadin, wheat, ID-1320 0.306 0.0048
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No. Protein A B/mM–1
21. tropomyosin b-chain, chicken, ID-1130 0.306 0.0040
22. a/b-gliadin [precursor] (prolamin)
(class A-V), wheat ID-1181
0.307 0.0080
23. a-2-purothionin [precursor], wheat, ID-1174 0.309 0.0046
24. a-lactalbumin, Arabian camel, ID-1085 0.309 0.0167
25. a-lactalbumin, horse, ID-1078 0.309 0.0088
26. a/b-gliadin [precursor] (prolamin)
(class A-III), wheat, ID-1180
0.312 0.0052
27. a/b-gliadin fragment (prolamin)
(clone PTO A10), wheat, ID-1186
0.312 0.0057
28. g-gliadin, wheat, ID-1317 0.312 0.0034
29. 12S seed storage globulin [precursor],
oat, ID-1167
0.315 0.0133
30. a-hordothionin [precursor] (purothionin
II), barley, ID-1176
0.315 0.0035
31. lysozyme C [precursor], chicken, ID-1092 0.315 0.0127
32. a-lactalbumin, cow, ID-1115 0.317 0.0095
33. sorghum kafirin PSK8 [precursor],
ID-1197
0.322 0.0043
34. a/b-gliadin [precursor] (prolamin)
(MM1), wheat, ID-1179
0.322 0.0067
35. g-gliadin [precursor] (class B-III), wheat,
ID-1148
0.322 0.0091
36. retinol binding protein RBP, cow, ID-1198 0.322 0.0066
37. k-casein, goat, ID-1109 0.323 0.0050
38. 11S globulin seed storage protein G3
[precursor], common sunflower, ID-1163
0.324 0.0098
39. a-1-purothionin [precursor] (fragment),
wheat, ID-1171
0.325 0.0101
40. g-gliadin, wheat, ID-1319 0.325 0.0051
41. a-lactalbumin, sheep, ID-1082 0.325 0.0120
42. a-lactalbumin, goat, ID-1079 0.325 0.0129
43. flavodoxin mutant D58P, ID-1108 0.326 0.0229
44. OBP, odorant binding protein, cow,
ID-1193
0.327 0.0102
45. sorghum kafirin PSKR2 [precursor],
ID-1196
0.330 0.0087
46. legumin chain B fragment, broad bean,
ID-1142
0.331 0.0011
47. b-globulin B (legumin), ID-1141 0.332 0.0124
48. a-lactalbumin, human, ID-1077 0.333 0.0089
49. chicken connectin (titin), fragment,
chicken, ID-1076
0.333 0.0104
50. a/b-gliadin [precursor] (prolamin)
(clone PW 1215), wheat, ID-1182
0.334 0.0059
51. legumin J, garden pea, ID-1144 0.334 0.0091
52. soybean basic 7S subunit globulin
[precursor], ID-1162
0.340 0.0150
53. lysozyme C, human [precursor], ID-1091 0.346 0.0119
54. g-hordein 1 [precursor], barley, ID-1150 0.348 0.0054
55. 11S globulin (b subunit) pumpkin,
ID-1161
0.350 0.0129
56. cocoa storage protein, ID-1114 0.351 0.0088
Table 1. – continued
No. Protein A B/mM–1
57. g-1-purothionin, wheat, ID-1172 0.362 0.0029
58. k-casein gen. var. A, cow, ID-1117 0.363 0.1563
59. a-S2-casein gen. var. A, cow, ID-1090 0.365 0.0099
60. troponin T, cardiac muscle isoforms,
cow, ID-1273
0.368 0.1100
61. rice prolamin [precursor] CLONE PPROL
14, ID-1154
0.372 0.0230
62. troponin C, pig, ID-1134 0.375 0.0074
63. human lactoferrin, ID-1121 0.377 0.0158
64. g-hordothionin, barley, ID-1175 0.383 0.0111
65. legumin 11S globulin, ginko, ID-1143 0.384 0.0105
66. bilin binding protein BBP, white butterfly,
ID-1199
0.386 0.0203
67. rice prolamin [precursor], CLONE
PPROL 4A, ID-1155
0.387 0.0223
68. myosin light chain, chicken (I), ID-1122 0.395 0.0047
69. Che Y, chemotactic protein (Escherichia
coli), ID-1106
0.403 0.0137
70. rice prolamin [precursor], CLONE
PPROL 7, ID-1152
0.409 0.0240
71. legumin-like protein, mouse-ear cress,
ID-1140
0.412 0.0130
72. blueberry monellin, B chain, ID-1169 0.420 0.0217
73. phycocyanin, ID-1126 0.420 0.0101
74. b-lactoglobulin, cow, gen. var. A, ID-1116 0.421 0.0269
75. plastocyanin, rice, ID-1564 0.422 0.0059
76. k-casein, human, ID-1120 0.456 0.0114
77. a-S1-casein gen. var. A, cow, ID-1086 0.462 0.0111
78. a-S1-casein gen. var. B, cow, ID-1087 0.467 0.0144
79. a-S1-casein gen. var. D, cow, ID-1089 0.467 0.0139
80. b-lactoglobulin, sheep, ID-1105 0.469 0.0295
81. a-S1-casein gen. var. C, cow, ID-1088 0.472 0.0143
82. b-lactoglobulin, goat, ID-1104 0.475 0.0295
83. epidermal retin acid binding protein EBP,
mouse-ear cress, ID-1200
0.491 0.0193
84. blueberry monellin, chain A, ID-1170 0.511 0.0214
85. b-casein gen. var. F, cow, ID-1103 0.536 0.0176
86. b-casein gen. var. A1, cow, ID-1097 0.545 0.0180
87. b-casein gen. var. A3, cow, ID-1099 0.545 0.0180
88. b-casein gen. var. C, cow, ID-1101 0.550 0.0180
89. wheat glutenin, high molecular mass
subunit PW212 [precursor], ID-1110
0.558 0.0190
90. b-casein gen. var. B, cow, ID-1100 0.558 0.0194
91. b-casein gen. var. A2, cow, ID-1098 0.565 0.0193
92. b-casein gen. var. E, cow, ID-1102 0.569 0.0193
93. collagen a-1(I) chain [precursor],
chicken, ID-1113
0.751 0.2340
94. collagen a-1(III) chain, cow, ID-1111 0.854 0.2740
95. collagen a-1(I) chain (fragment), cow,
ID-1112
0.874 0.2720
96. elastin [precursor] (tropoelastin), cow,
ID-1107
0.885 0.0209
Table 2 presents the idea of comparison of the major
groups of proteins as precursors of ACE inhibitors. A
statistical t-test for independent variables was performed
using Statistica v. 8 software. For example, the values of
A for one group of proteins were compared with A for
another group of proteins. The same rule referred to po-
tential ACE inhibitory activity (B values of one group vs.
B for another group). All statistically significant differ-
ences were obtained at p<0.05. Significant differences
were not observed between the following groups: wheat
gliadins vs. chicken troponins, wheat gliadins vs. chick-
en meat proteins, rice proteins vs. chicken meat proteins.
Mean potential ACE inhibitory activity (B) suggests that
b-lactoglobulins are a source of less potent ACE inhibi-
tory peptides than soy globulins. The same conclusion
refers to the wheat gliadins vs. rice prolamins. The mean
frequencies of the occurrence of ACE inhibitors in the
above-mentioned groups of proteins are approximately
at the same level. The t-test confirmed the results in Table
1: e.g. although b-caseins are a better potential source of
ACE inhibitors than a-S1-caseins (significance at p<0.05),
the latter possess more potent peptides with this activ-
ity. b-Lactoglobulins are a richer source of ACE inhibi-
tory peptides than a-lactalbumins from different sour-
ces, lysozymes or a/b-wheat gliadins (and all analyzed
gliadins).
Comparing the above-mentioned three criteria of
protein evaluation, it can be said that although the po-
tential ACE inhibitory activity of protein (B) is a more
accurate measure of protein value, the other two criteria
such as the profile of potential ACE inhibitory activity
of protein as well as the frequency of the occurrence of
fragments with ACE inhibitory activity (A) can be used
for that purpose more widely. This is due to the fact that
the calculation of B requires information about the IC50
(the concentration required to inhibit 50 % of the ACE
activity). The values of the above-mentioned measure may
depend on the assay. Murray et al. (21) found that the
IC50 values obtained for a known ACE inhibitor, capto-
pril, ranged from 5 to 23 nM using HHL and from 1.61
to 8.91 nM when using FAPGG to determine ACE activ-
ity. Detailed information on the number of enzyme units
applied in all ACE inhibition analyses seems to be es-
sential for comparable purposes. The comparison of IC50
values obtained for different substances can be more mean-
ingful if the IC50 value for a standard like captopril is re-
ported (21).
Despite these obstacles, the in silico methods applied
in the determination of protein value as the potential
precursors of peptides with various activities can be a
preliminary 'qualifier' of protein in functional food man-
ufacturing, especially nutraceuticals, i.e. food with spe-
cial therapeutic properties (5). Moreover, detection of
functional motifs (i.e. ACE inhibitory fragments) in a
protein sequence can reveal the protein's function and,
consequently, it can be assigned to the evolutionarily re-
lated protein family (28). Dziuba et al. (30) analyzed bo-
vine b-lactoglobulin and other protein sequences from
the lipocalin family and found some similar domains
containing fragments with different bioactivities, includ-
ing ACE inhibitory ones. This confirms the contempo-
rary approach that proteins with similar sequences and
spatial structures can play different roles in living sys-
tems (31). This rule may also be applied to proteins as
the source of ACE inhibitory peptides.
Conclusions
The criteria for protein evaluation presented in this
paper are suitable measures to identify which plant or
animal proteins could serve as a potentially good source
of peptides with ACE inhibitory activity. The profile of
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Table 2. The results of t-test for various protein groups
Proteins Mean A Mean B
t-value
Significant
at pGroup 1 vs. Group 2 Group 1 Group 2 Group 1 Group 2
b-caseins a-S1-caseins 0.552 0.465 – – 12.148 <0.05
– – 0.0185 0.0131 6.983 <0.05
b-lactoglobulins a-lactalbumins 0.455 0.304 – – 7.496 <0.05
– – 0.0286 0.0103 8.907 <0.05
b-lactoglobulins lysozymes 0.455 0.310 – – 7.788 <0.05
– – 0.0286 0.0100 9.658 <0.05
b-lactoglobulins a/b-wheat gliadins 0.455 0.313 – – 12.619 <0.05
– – 0.0286 0.0060 22.512 <0.05
b-lactoglobulins wheat gliadins 0.455 0.310 – – 15.038 <0.05
– – 0.0286 0.0060 21.978 <0.05
soybean globulins b-lactoglobulins 0.340 0.455 – – –3.360 –
– – 0.0150 0.0064 5.164 <0.05
wheat gliadins chicken troponins 0.310 0.304 – – 0.514 –
– – 0.0639 0.0066 –0.124 –
wheat gliadins chicken meat proteins 0.310 0.383 – – –1.737 –
– – 0.0639 0.0393 –1.530 –
rice proteins wheat gliadins 0.334 0.310 – – 1.256 –
– – 0.155 0.0639 3.977 <0.05
rice proteins chicken meat proteins 0.334 0.383 – – –0.659 –
– – 0.155 0.0393 –0.730 –
the potential biological activity of a protein, as well as
the frequency of the occurrence of fragments with bio-
logical activity (A) can be applied to evaluate proteins
as a source of peptides with other activities. These re-
sults confirmed that genetic variants of bovine caseins
are the best sources of ACE inhibitors. Among the other
analyzed sequences, it was found that soy globulins can
be a better source of these peptides than bovine b-lac-
toglobulins. All wheat gliadins gathered in BIOPEP can
be better precursors of ACE inhibitory fragments than
chicken meat proteins. However, it needs to be consid-
ered that: (i) proteolytic processes determine the poten-
tial release of such peptides from the protein; (ii) the re-
liability and accuracy of in silico methods in protein
evaluation is often subjective due to discretion in the in-
terpretation of the results (depending on the different al-
gorithms applied in biochemistry, molecular biology,
comparative modeling); and (iii) to date, unequivocal
rules in protein classification have not been established.
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